---
title: "Jeevan Scientific Technology Ltd (538837) — Share Price, Financials & Analysis"
symbol: "538837"
company: "Jeevan Scientific Technology Ltd"
canonical: "https://tapetide.com/stocks/538837"
isin: "INE237B01018"
nse_symbol: "JEEVANSCIENTIFICTECHNOLOGYLTD"
bse_code: "538837"
sector: "Healthcare"
industry: "Healthcare Technology"
market_cap_cr: 161.73
generated_at: "2026-09-13T18:37:06.357Z"
---

# Jeevan Scientific Technology Ltd (538837)

Canonical page: https://tapetide.com/stocks/538837

## Company

- **NSE Symbol:** JEEVANSCIENTIFICTECHNOLOGYLTD
- **BSE Code:** 538837
- **ISIN:** INE237B01018
- **Sector:** Healthcare
- **Industry:** Healthcare Technology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** jeevanscientific.com

## About

Incorporated in 1999, Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization which offers technology-driven clinical research solutions[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:39:41.450433Z.

- **Market Cap:** ₹161.73 Cr
- **Classification:** Microcap
- **P/E (reported):** 32
- **EPS (TTM):** ₹1.92
- **EPS (reported):** ₹0
- **Book Value:** ₹35.91
- **Price to Book:** 2.27
- **Dividend Yield:** 1.47%
- **ROE:** 0.12%
- **ROCE:** 2.74%
- **Debt to Equity:** 0.3
- **Revenue (yearly):** ₹61.54 Cr
- **Net Income:** ₹1.98 Cr
- **EBITDA:** ₹9.8 Cr
- **52-Week High:** ₹93.9
- **52-Week Low:** ₹32.85
- **RSI (14):** 63.02

## Tapetide Score

- **Score:** 55 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 70.1 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 50.35 | 9% |
| growth | 96.75 | 9% |
| momentum | 66.69 | 12% |
| ownership | 50 | 24% |
| quality | 49.6 | 22% |
| valuation | 44.05 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 30.2%
- Company has a low return on equity of -0.01% over last 3 years.
- Promoter holding has decreased over last 3 years: -8.23%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 248.44% | 257.1% | 103.43% |
| ebitda margin growth | -32.61% | -7.66% | 19.42% | -49.04% |
| net income growth | -50% | — | 33% | -37% |
| revenue growth | -14.35% | 29.56% | 19% | 6% |
| roce | -52.19% | -353.7% | -155.8% | 13.52% |
| roe | -52.72% | -104.4% | -2.98% | -99.64% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 8.06 | 10.13 | 11.07 | 12.88 | 11.4 | 12.51 | 10.06 | 8.8 | 12.38 | 19.07 | 21.29 | 18.28 |
| Expenses | 7.46 | 9.12 | 10.09 | 9.65 | 8.9 | 10.44 | 10.44 | 10.58 | 10.31 | 13.84 | 17 | 15.33 |
| Operating Profit | 0.6 | 1.01 | 0.98 | 3.23 | 2.5 | 2.07 | -0.38 | -1.78 | 2.07 | 5.23 | 4.29 | 2.95 |
| OPM % | 7.44 | 9.97 | 8.85 | 25.08 | 21.93 | 16.55 | -3.78 | -20.23 | 16.72 | 27.43 | 20.15 | 16.14 |
| Other Income | 0.26 | -0.11 | 0.23 | 0.11 | 0.16 | 0.23 | 0.15 | 0.33 | 0.2 | 0.14 | 0.29 | 0.17 |
| Interest | 0.26 | 0.15 | 0.33 | 0.33 | 0.45 | 0.43 | 0.55 | 0.54 | 0.55 | 0.54 | 0.41 | 0.44 |
| Depreciation | 1.43 | 1.4 | 1.64 | 1.51 | 1.49 | 1.48 | 1.77 | 1.74 | 1.69 | 1.6 | 1.61 | 1.7 |
| Profit before tax | -0.83 | -0.65 | -0.76 | 1.5 | 0.72 | 0.39 | -2.55 | -3.73 | 0.03 | 3.23 | 2.56 | 0.98 |
| Tax % | -25.3 | -24.62 | -3.95 | 31.33 | 65.28 | 89.74 | -50.59 | -13.67 | 66.67 | 25.7 | 28.52 | 11.22 |
| Net Profit | -0.61 | -0.49 | -0.73 | 1.03 | 0.25 | 0.05 | -1.26 | -3.22 | 0.01 | 2.4 | 1.84 | 0.87 |
| EPS in Rs | -0.39 | -0.31 | -0.47 | 0.7 | 0.16 | 0.07 | -0.82 | -1.96 | -0.06 | 0.9 | 0.81 | 0.27 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 20.39 | 26.13 | 23.94 | 46.9 | 67.79 | 36.18 | 39.65 | 46.84 | 61.54 | 71.02 |
| Expenses | 16.96 | 20.27 | 30.02 | 29.41 | 51.02 | 34.82 | 35.01 | 39.37 | 51.74 | 56.48 |
| Operating Profit | 3.43 | 5.86 | -6.08 | 17.49 | 16.77 | 1.36 | 4.64 | 7.47 | 9.8 | 14.54 |
| OPM % | 16.82 | 22.43 | -25.4 | 37.29 | 24.74 | 3.76 | 11.7 | 15.95 | 15.92 | 20.47 |
| Other Income | 0.92 | 1 | 2.5 | 2.39 | 5.91 | 1.07 | 0.67 | 0.65 | 0.97 | 0.8 |
| Interest | 1.87 | 2.36 | 3.04 | 2.26 | 0.96 | 1.04 | 0.98 | 1.82 | 2.04 | 1.94 |
| Depreciation | 2.12 | 3.13 | 3.92 | 3.97 | 3.69 | 5.07 | 5.93 | 6.25 | 6.64 | 6.6 |
| Profit before tax | 0.36 | 1.37 | -10.54 | 13.65 | 18.03 | -3.68 | -1.6 | 0.05 | 2.09 | 6.8 |
| Tax % | 69.44 | 18.25 | -18.6 | 13.99 | 33.78 | -16.58 | -17.5 | -20 | 50.72 | — |
| Net Profit | 0.11 | 1.11 | -8.59 | 11.74 | 11.94 | -3.07 | -1.33 | 0.05 | 1.03 | 5.12 |
| EPS in Rs | 0.1 | 0.73 | -5.61 | 7.67 | 7.8 | -1.97 | -0.84 | 0.08 | 0.58 | 1.92 |
| Dividend Payout % | 0 | 0 | 0 | 6.52 | 15.38 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 9.28 | 11.46 | 15.3 | 15.3 | 15.3 | 15.3 | 15.48 | 15.48 | 15.83 | 19.92 |
| Reserves | 7.6 | 10.55 | 16.53 | 7.92 | 19.72 | 35.28 | 32.71 | 32.95 | 34.11 | 52.02 |
| Borrowings | 8.45 | 18.78 | 18.15 | 17.95 | 10.34 | 12.55 | 10.1 | 13.41 | 20.58 | 21.28 |
| Other Liabilities | 5.56 | 8.59 | 11.32 | 12.7 | 20.62 | 14.75 | 7.63 | 6.03 | 7.77 | 13.37 |
| Total Liabilities | 30.89 | 49.38 | 61.3 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 78.29 | 106.59 |
| Fixed Assets | 16.35 | 28.17 | 32.59 | 30.54 | 27.38 | 19.07 | 24.97 | 26.66 | 34.55 | 36.08 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1.9 | 2.81 | 4.71 | 4.71 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.98 |
| Other Assets | 14.54 | 21.21 | 28.71 | 23.33 | 38.6 | 58.81 | 39.05 | 38.4 | 39.03 | 62.82 |
| Total Assets | 30.89 | 49.38 | 61.3 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 78.29 | 106.59 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -5.62 | 5.65 | 4.04 | -0.01 | 4.95 | 19.56 | -6.41 | 2.89 | 10.07 | 0.42 |
| Cash from Investing Activity | -8.9 | -14.35 | -7.87 | -1.9 | -0.8 | -1.2 | -6.93 | -11.53 | -15.62 | -9.98 |
| Cash from Financing Activity | 14.57 | 9.86 | 6.08 | 0.44 | -0.13 | 5.67 | -9.54 | 2.35 | 5.24 | 18.83 |
| Net Cash Flow | 0.05 | 1.17 | 2.25 | -1.47 | 4.02 | 24.03 | -22.88 | -6.29 | -0.3 | 9.26 |
| Free Cash Flow | -14.52 | -8.7 | -3.83 | -1.91 | 4.15 | 17.33 | -14.57 | -9.14 | -5.96 | -7.76 |
| CFO/OP | -176 | 165 | 69 | 32 | 39 | 153 | -269 | 101 | 135 | 5 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 227.1 | 291.79 | 205.2 | 104.29 | 112.46 | 40.97 | 117.83 | 113.14 | 124.21 | 122.71 |
| Inventory Days | — | — | — | — | — | 72.11 | 105.5 | 104.15 | 155.61 | 226.63 |
| Days Payable | — | — | — | — | — | 98.78 | 322.56 | 205.43 | 305.45 | 458.49 |
| Cash Conversion Cycle | 227.1 | 291.79 | 205.2 | 104.29 | 112.46 | 14.3 | -99.23 | 11.85 | -25.63 | -109.15 |
| Working Capital Days | 90.6 | 35.44 | -3.07 | -100.78 | 37.36 | 10.18 | 110.67 | 137.35 | 128.19 | 121.41 |
| ROCE % | 12.69 | 6.75 | 8.22 | -16.39 | 36.77 | 27.58 | -4.34 | -1.03 | 2.8 | 5.01 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 38.48% | 38.48% | 38.7% | 38.7% | 38.7% | 37.84% | 38.05% | 38.05% | 38.05% | 38.05% | 30.25% | 30.25% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 45.98% | 45.51% | 45.5% | 45.34% | 45.75% | 45.91% | 42.99% | 42.75% | 42.76% | 46.56% | 55.79% | 55.8% |
| Others | 15.53% | 16% | 15.8% | 15.96% | 15.55% | 16.25% | 18.96% | 19.21% | 19.19% | 15.39% | 13.96% | 13.95% |
| No. of Shareholders | 5933 | 5727 | 5749 | 5655 | 5607 | 5565 | 5497 | 5460 | 5444 | 5159 | 5053 | 4966 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 5 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 76.83 | Buy |
| EMA (10) | 78.2 | Buy |
| SMA (20) | 75.75 | Buy |
| EMA (20) | 76.97 | Buy |
| SMA (50) | 75.13 | Buy |
| EMA (50) | 76.43 | Buy |
| SMA (100) | 78.31 | Buy |
| EMA (100) | 75.39 | Buy |
| SMA (200) | 71.91 | Buy |
| EMA (200) | 70.4 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 63.77 | Neutral |
| MACD (12,26,9) | 1.1 | Buy |
| Stochastic (14,3,3) | 80.27 | Sell |
| ADX (14) | 18.66 | Neutral |
| Williams %R (14) | -21.6 | Neutral |
| ATR (14) | 4.28 | High Volatility |
| ROC (12) | 10.43 | Buy |
| Stoch RSI (14) | 95.88 | Sell |
| UO (7,14,28) | 47.55 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8de2370-43e7-4c82-8e30-292de70986cb.pdf) |
| 2026-09-03 | [28Th Annual General Meeting Of The Company Is Schecduled To Be Held On 25.09.2026 At 10:00 A.M.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bf2bda3-015b-4472-932e-954999854ceb.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2efc403-6406-4e4f-bba5-19741b7fca81.pdf) |
| 2026-08-13 | [Board Meeting Outcome for Outcome Of The Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53935557-6404-443f-9815-6219bdbb56ce.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58f15553-d3a2-4cc8-afc3-eb150c969dc5.pdf) |
| 2026-08-13 | [Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa6ccf01-6879-4e38-bc03-56a9b628c7cd.pdf) |
| 2026-08-10 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 13.08.2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1949d059-ce29-41bc-a42b-2b93ee53996e.pdf) |
| 2026-08-01 | [Intimation Of Approval For Addition Of Beds To The Existing Approved Bioavailability/ Bioequivalence Center Of Jeevan Scientific Technology Limiteds Bioavailability/Bioequivalence.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=84e067d5-0dcc-4924-bca3-72242431ee57.pdf) |
| 2026-07-24 | [Information About The Successful Completion Of USFDA Inspection.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3efd4d7-2876-4129-9dc1-221ab0437af0.pdf) |
| 2026-07-16 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=556d35ce-a085-4358-bc34-06262eb1246d.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Unaudited Financial Results (Standalone And Consoilidated) For The Quarter Ended 30.06.2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b958fb8e-6e67-4320-82b0-281d5a0752ec.pdf) |
| 2026-05-29 | [Audited Financial Results For The Quarter And Year Ended 31.03.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e98640fb-b638-4f70-8569-659bc951125c.pdf) |
| 2026-02-11 | [Unaudited Financial Results For The Quarter Ended 31-12-2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e149d78-9739-493d-af71-eb6715ee6eee.pdf) |
| 2025-11-12 | [Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9aeefdc9-c6cb-4ade-aa55-a969ecb91b6b.pdf) |
| 2025-08-14 | [Un Audited Financial Results For The Quarter Ended 30.06.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae3239e6-d720-4b87-bf48-9b32abff420a.pdf) |
| 2025-05-30 | [Audited Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended 30.05.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4f3431e-1039-426a-8d06-857997cded0b.pdf) |
| 2025-02-06 | [Un Audited Results For The Quarter And Nine Months Ended 31.12.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=807ddf61-4761-4911-9a86-3c8a1ccb0af0.pdf) |
| 2024-11-08 | [Un Audited Financial Results ( Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb99489d-00f9-49c8-94a9-b9957f22f380.pdf) |
| 2024-08-09 | [Unaudited Financial Results For The Quarter Ended 30.06.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e433983c-18d8-4447-8a05-2d10a9e8c4a7.pdf) |
| 2024-05-30 | [Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended 31.03.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2505c6d-697a-4e9d-9f0d-dd2390a43919.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 Jan - Padmaja Private Trust allotted 1,500,000 shares (7.53%) via preferential allotment on 02-01-2026. | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 7 Jan - Padmaja Private Trust allotted 1,500,000 shares (7.53%) via preferential allotment on 02-01-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6518BCC7_5530_43E8_BB90_46F8B4007DED_170033.pdf) |
| 30 Apr - Company says it is not a Large Corporate; initial disclosure not applicable for FY 2026-27. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Company says it is not a Large Corporate; initial disclosure not applicable for FY 2026-27.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/39f492b8-93d1-4e69-a2ad-0a1f9eb8c5a1.pdf) |
| 30 Apr - Company says it is not a Large Corporate; initial disclosure not applicable for FY 2026-27. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Company says it is not a Large Corporate; initial disclosure not applicable for FY 2026-27.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/39f492b8-93d1-4e69-a2ad-0a1f9eb8c5a1.pdf) |
| 30 Apr - Company confirms it is not a Large Corporate; FY2026-27 initial disclosure not applicable, outstanding borrowing Rs.11.58 crore. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Company confirms it is not a Large Corporate; FY2026-27 initial disclosure not applicable, outstanding borrowing Rs.11.58 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b803549-642c-441c-a90f-ab7bfaba9d1f.pdf) |
| 30 Apr - Company confirms it is not a Large Corporate; FY2026-27 initial disclosure not applicable, outstanding borrowing Rs.11.58 crore. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Company confirms it is not a Large Corporate; FY2026-27 initial disclosure not applicable, outstanding borrowing Rs.11.58 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5b803549-642c-441c-a90f-ab7bfaba9d1f.pdf) |
| 30 Apr - Company confirms it is not a Large Corporate for FY2025-26 under SEBI debt framework. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Company confirms it is not a Large Corporate for FY2025-26 under SEBI debt framework.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1667f73-239b-45d1-bfb0-22796771708d.pdf) |
| 30 Apr - Company confirms it is not a Large Corporate for FY2025-26 under SEBI debt framework. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Company confirms it is not a Large Corporate for FY2025-26 under SEBI debt framework.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f1667f73-239b-45d1-bfb0-22796771708d.pdf) |
| 30 Apr - Annual disclosure for FY2025-26 confirms Jeevan Scientific is not a large corporate; no debt borrowing. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Annual disclosure for FY2025-26 confirms Jeevan Scientific is not a large corporate; no debt borrowing.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ee26f1fb-b282-4611-add0-eb36849a0b1d.pdf) |
| 30 Apr - Annual disclosure for FY2025-26 confirms Jeevan Scientific is not a large corporate; no debt borrowing. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Annual disclosure for FY2025-26 confirms Jeevan Scientific is not a large corporate; no debt borrowing.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ee26f1fb-b282-4611-add0-eb36849a0b1d.pdf) |
| 22 Jan - US FDA concluded remote assessment (17 Oct–6 Nov 2025) at JSTL Hyderabad clinical pharmacology facility; report issued. | [Closure Of The United States Food And Drug Administration (US FDA) Remote Regulatory Assessment Of JSTL And Issuance Of The Remote Regulatory Assessment Report - Corporate Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 22 Jan - US FDA concluded remote assessment (17 Oct–6 Nov 2025) at JSTL Hyderabad clinical pharmacology facility; report issued.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a6c29fb8-f40d-4b88-bb45-6adc16288157.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/92155d9c-1ad4-44e1-9a93-6255050000ef.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d0eba62a-14a1-4186-bd7f-2fcdc2f56f16.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/493e87c7-dcb1-4883-a525-81669195fcc3.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/76088538837.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/69720538837.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/66559538837.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/5388370319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/5388370318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/5388370317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/538837/5388370316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:06.357Z.